Shineco Surges 36.97 on $210M Volume Spike Ranking 475th as Blockchain Biotech Pivot Fuels Tokenization Push

On August 20, 2025, Shineco (NASDAQ: SISI) surged 36.97% to $6.78, driven by a $0.21 billion trading volume—a 180,488.46% jump from the previous day—ranking it 475th in market activity. The stock’s volatility underscores investor reaction to the company’s strategic pivot into blockchain-based biotech infrastructure. Shineco announced a partnership with Plus Me Limited to launch the first Ethereum-based platform for tokenizing cellular assets, including "Cell Infusion Redemption Tokens" compliant with ERC-1400/ERC-20 standards. This initiative integrates non-fungible digital identifiers (NFDIs) for asset traceability and smart contracts to enforce regulatory compliance.

The company’s 51% acquisition of Xi’an Dong’ao Health Management, a cryogenic cell storage specialist, complements its Singapore-based Infiniclone operations, creating a global network to bridge on-chain tokens with physical cell therapies. This infrastructure aims to address liquidity challenges in biotech assets while enabling programmable redemption mechanisms. The token burning model upon redemption introduces scarcity dynamics, aligning with broader institutional interest in real-world asset tokenization. Shineco’s CEO emphasized the platform’s potential to redefine the biotech economy by transforming cellular assets into tradable, verifiable instruments.

A strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a 31.52% total return over 365 days, with a 0.98% average daily gain. The approach peaked at 7.02% in June 2023 but faced a -4.20% decline in September 2022, reflecting market volatility. This pattern highlights the strategy’s reliance on short-term momentum, making it suitable for traders prioritizing liquidity over long-term stability.